瑞舒伐他汀对高血压病患者动脉粥样硬化及心功能的影响

目的探讨瑞舒伐他汀对高血压病患者动脉粥样硬化及心功能的影响。方法入选门诊高血压病患者178例，随机分为瑞舒伐他汀治疗组（10mg／天，睡前）、氟伐他汀治疗组（40mg/天），治疗随访8个月。治疗前及后行超声心动图、核素心血池检查和血清肿瘤坏死因子-α（TNF-α）、基质金属蛋白酶（MMPs）等检查，并进行对比分析。结果治疗后瑞舒伐他汀组总胆同醇（3．1±0．6）mmol／L、LDL胆固醇（2．0±0．4）mmol／L、颈动脉内膜中层厚度（0．80±0．27）mm、冠状动脉钙化积分LN（1．64±1．48）分；氟伐他汀组总胆固醇（4．3±0.8）mmol／L、LDL胆固醇（2．5±0．6）mmol／L、颈动脉内膜中层厚度（0．86±0．27）mm、冠状动脉钙化积分LN（1．87±1．71）分，两组较治疗前，差异有极显著性（P〈0．01），治疗后两组对比差异有显著性（P〈0．05）。治疗后瑞舒伐他汀组LVEF（60．25±11．05）％，LVPFR（2．89±0．67）；氟伐他汀组LVEF（61．01±8．95）％，LVPFR（2．29±0．63），较治疗前，差异有极显著性（P〈0．01），治疗后两组对比差异有显著性（P〈0．05）。结论瑞舒伐他汀治疗可进一步缓解高血压病患者的动脉粥样硬化和改善其心功能，其机制可能与降低血清TNF-α及MMPs有关。

Effect of rosuvastatin on the progress of arteriosclerosis and cardiac function in patients with essential hypertension

Objective To explore the effect of rosuvastatin on the progress of arteriosclerosis and cardiac function in patients with essential hypertension. Methods 178 clinic patients were randomly as signed to receive rosuvastatin (Astrazeneca) of 10 mg daily (91 patients, rosuvastatin group), or fluvastatin (Lescol) of 40 mg dialy (87 patients, fluvastatin group) for 8 months. Ultrasonography and cardiac function examinatin were performed and serum levels of matrix metalloproteinase (MMPs) and TNF-α, were detected before and after treatment. Results The baseline findings were similar in the two groups. After 8-month therapy, serum levels of total cholesterol, LDL, TNF-α, MMPs-2, and MMPs-9 were decreased and the intima media thickness of the common carotid artery and the plaque size in the coronary artery were declined in both groups, especially in rosuvastatin group (P<0.01 for all comparisons). LVPFR increased markedly in rosuvastatin group. LVEF and LVPFR were higher in rosuvastatin group than in fluvastatin group. Conclu sions Rosuvastatin therapy can relieve plaque formation and improve left ventricular function in patients with hyertension, whose mechanism may be involved in the decrease in serum levels of TNF-α, and MMPs.